[144] Guardant Health, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Guardant Health, Inc. (GH) shows an intended sale of 116 common shares via Charles Schwab on 09/17/2025 with an aggregate market value of $6,453. The shares were acquired on 09/15/2025 through a restricted stock lapse under equity compensation. The filing lists prior open-market sales by the same account in the past three months: 3,213 shares for $158,947 on 06/18/2025, and two smaller sales of 116 shares$5,591 and $6,846 on 07/17/2025 and 08/19/2025, respectively. The signer affirms no undisclosed material adverse information.

Positive

• Discloses acquisition source (restricted stock lapse), improving transparency
• Includes recent sales history for the same account, aiding compliance and investor visibility
• Identifies broker and planned sale date, giving execution clarity

Negative

• Insider liquidity activity — multiple recent sales including a 3,213-share sale, which may concern some investors

Insights

Securities Analyst

TL;DR: Insider selling activity includes a new small sale tied to restricted stock lapse and multiple recent open-market dispositions.

The filing documents a proposed sale of 116 shares following a restricted stock lapse, with execution through a retail brokerage. Recent transactions show substantial prior selling (3,213 shares for $158,947) plus two 116-share sales, indicating ongoing monetization of holdings rather than a single disposition. For investors, this is a disclosure of insider liquidity rather than a corporate operational signal; the amounts disclosed here are small relative to large-cap volumes but are material for transparency and compliance monitoring.

Corporate Governance Expert

TL;DR: The Form 144 appears procedurally complete and cites equity compensation as the acquisition source.

The notice properly identifies the nature of acquisition as a restricted stock lapse and names the broker and planned sale date. It also summarizes prior sales by the same person in the last three months, fulfilling Rule 144 disclosure expectations. The signer’s representation about lack of undisclosed material adverse information is included, aligning with regulatory attestation norms.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	116	6453.00	124705857	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2025	Restricted Stock Lapse	Guardant Health, Inc.			116	09/15/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	06/18/2025	3213	158947.00
Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	07/17/2025	116	5591.00
Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	08/19/2025	116	6846.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the Guardant Health (GH) Form 144?

The notice reports a proposed sale of 116 common shares acquired via a restricted stock lapse, to be sold through Charles Schwab on 09/17/2025 with aggregate market value $6,453.

Who has recently sold Guardant Health shares according to this filing?

The filing lists sales by Musa Tariq of 3,213 shares for $158,947 on 06/18/2025, and two sales of 116 shares on 07/17/2025 (for $5,591) and 08/19/2025 (for $6,846).

How were the 116 shares to be sold acquired?

They were acquired on 09/15/2025 through a restricted stock lapse under equity compensation, with payment characterized as equity compensation.

Through which broker will the proposed sale be executed?

The planned sale is to be executed through Charles Schwab & Co., Inc. and will trade on NASDAQ.

Does the filing assert absence of undisclosed material information?

Yes; the signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.